Darbepoetin in Neonatal Encephalopathy Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 28, 2021

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2024

Conditions
Neonatal Encephalopathy
Interventions
DRUG

Darbepoetin Alfa

Administration of Darbepoetin Alpha (10 mcg/kg) IV x2 doses following cooling therapy.

Trial Locations (9)

Unknown

NOT_YET_RECRUITING

Birmingham Womens Hospital, Birmingham

NOT_YET_RECRUITING

Bradford Teaching Hospitals NHS Foundation Trust, Bradford

NOT_YET_RECRUITING

Cambridge University Hospitals NHS Foundation Trust, Cambridge

RECRUITING

Medway NHS Foundation Trust, Gillingham

NOT_YET_RECRUITING

Liverpool Womens NHS Foundation Trust, Liverpool

RECRUITING

Homerton University Hospital, London

RECRUITING

Imperial College Healthcare Trust, London

RECRUITING

Bedfordshire Hospitals NHS Foundation Trust, Luton

RECRUITING

The Newcastle Upon Tyne NHS Foundation Trust, Newcastle

All Listed Sponsors
lead

Imperial College London

OTHER